These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8830931)

  • 1. Apolipoprotein E1-Hammersmith (Lys146-->Asn;Arg147-->Trp), due to a dinucleotide substitution, is associated with early manifestation of dominant type III hyperlipoproteinaemia.
    Hoffer MJ; Niththyananthan S; Naoumova RP; Kibirige MS; Frants RR; Havekes LM; Thompson GR
    Atherosclerosis; 1996 Aug; 124(2):183-9. PubMed ID: 8830931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe type III hyperlipoproteinemia associated with unusual apolipoprotein E1 phenotype and epsilon 1/'null' genotype.
    Feussner G; Funke H; Weng W; Assmann G; Lackner KJ; Ziegler R
    Eur J Clin Invest; 1992 Sep; 22(9):599-608. PubMed ID: 1360898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compound heterozygote for both rare apolipoprotein E1 (Gly127-->Asp, Arg158-->Cys) and E3(Cys112-->Arg, Arg251-->Gly) alleles in a multigeneration pedigree with hyperlipoproteinaemia.
    Richard P; Beucler I; Pascual De Zulueta M; Biteau N; De Gennes JL; Iron A
    Clin Sci (Lond); 1997 Jul; 93(1):89-95. PubMed ID: 9279208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein E-1Harrisburg: a new variant of apolipoprotein E dominantly associated with type III hyperlipoproteinemia.
    Mann WA; Gregg RE; Sprecher DL; Brewer HB
    Biochim Biophys Acta; 1989 Oct; 1005(3):239-44. PubMed ID: 2804053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Severe type III hyperlipoproteinemia with unusual lipoprotein phenotype in an adolescent patient].
    Ziemer A; Göring HD
    Hautarzt; 1993 Aug; 44(8):538-44. PubMed ID: 8376110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variable expression of familial dysbetalipoproteinemia in apolipoprotein E*2 (Lys146-->Gln) Allele carriers.
    de Knijff P; van den Maagdenberg AM; Boomsma DI; Stalenhoef AF; Smelt AH; Kastelein JJ; Marais AD; Frants RR; Havekes LM
    J Clin Invest; 1994 Sep; 94(3):1252-62. PubMed ID: 8083367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein EBethesda: a new variant of apolipoprotein E associated with type III hyperlipoproteinemia.
    Gregg RE; Ghiselli G; Brewer HB
    J Clin Endocrinol Metab; 1983 Nov; 57(5):969-74. PubMed ID: 6578216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triglyceride-rich lipoproteins of subjects heterozygous for apolipoprotein E2(Lys146-->Gln) are inefficiently converted to cholesterol-rich lipoproteins.
    Mulder M; van der Boom H; de Knijff P; Braam C; van den Maagdenberg A; Leuven JA; Havekes LM
    Atherosclerosis; 1994 Aug; 108(2):183-92. PubMed ID: 7980718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Familial dysbetalipoproteinemia: a genetically heterogenous disease caused by mutations of the ligand apolipoprotein E.
    Vermeer BJ; Frants RR; Havekes LM
    J Invest Dermatol; 1992 Jun; 98(6 Suppl):57S-60S. PubMed ID: 1588125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dominant expression of type III hyperlipoproteinemia. Pathophysiological insights derived from the structural and kinetic characteristics of ApoE-1 (Lys146-->Glu).
    Mann WA; Lohse P; Gregg RE; Ronan R; Hoeg JM; Zech LA; Brewer HB
    J Clin Invest; 1995 Aug; 96(2):1100-7. PubMed ID: 7635945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic heterogeneity of apolipoprotein E and its influence on plasma lipid and lipoprotein levels.
    de Knijff P; van den Maagdenberg AM; Frants RR; Havekes LM
    Hum Mutat; 1994; 4(3):178-94. PubMed ID: 7833947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hyperlipoproteinemia type III with apolipoprotein E phenotype 2/2].
    Engst R
    Hautarzt; 1985 Nov; 36(11):629-34. PubMed ID: 4077508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tuberous xanthomas associated with olanzapine therapy and hypertriglyceridemia in the setting of a rare apolipoprotein E mutation.
    Sinnott BP; Mazzone T
    Endocr Pract; 2006; 12(2):183-7. PubMed ID: 16690468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apolipoprotein E1 Baden (Arg(180)-->Cys). A new apolipoprotein E variant associated with hypertriglyceridemia.
    Hoffmann MM; Scharnagl H; Köster W; Winkler K; Wieland H; März W
    Clin Chim Acta; 2001 Jan; 303(1-2):41-8. PubMed ID: 11163021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [From gene to disease; apolipoprotein E2 and familial dysbetalipoproteinemia].
    Smelt AH
    Ned Tijdschr Geneeskd; 2003 Jan; 147(4):157-9. PubMed ID: 12635547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype.
    Kypreos KE; Li X; van Dijk KW; Havekes LM; Zannis VI
    Biochemistry; 2003 Aug; 42(33):9841-53. PubMed ID: 12924933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a new apolipoprotein E variant (E2 Arg142-->Leu) in type III hyperlipidemia.
    Richard P; de Zulueta MP; Beucler I; De Gennes JL; Cassaigne A; Iron A
    Atherosclerosis; 1995 Jan; 112(1):19-28. PubMed ID: 7772063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Normolipemic dysbetalipoproteinemia and hyperlipoproteinemia type III in subjects homozygous for a rare genetic apolipoprotein E variant (apoE1).
    Steinmetz A; Assefbarkhi N; Eltze C; Ehlenz K; Funke H; Pies A; Assmann G; Kaffarnik H
    J Lipid Res; 1990 Jun; 31(6):1005-13. PubMed ID: 1973700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysbetalipoproteinaemia--clinical and pathophysiological features.
    Blom DJ; Byrnes P; Jones S; Marais AD
    S Afr Med J; 2002 Nov; 92(11):892-7. PubMed ID: 12506591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atorvastatin markedly improves type III hyperlipoproteinemia in association with reduction of both exogenous and endogenous apolipoprotein B-containing lipoproteins.
    Ishigami M; Yamashita S; Sakai N; Hirano K; Hiraoka H; Nakamura T; Matsuzawa Y
    Atherosclerosis; 2003 Jun; 168(2):359-66. PubMed ID: 12801620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.